Current Issue

September 2014

Benefits outweigh harms of aspirin therapy
Prophylactic aspirin therapy of at least 5 years’ duration has a favorable benefit-harm profile, primarily because of its effectiveness in preventing colorectal and other cancers, according to a report in the August issue of Annals of Oncology.

Simulation model projects HCV to be rare by 2026
A simulation model that incorporated a onetime universal screening of U.S. adults for hepatitis C virus and made conservative assumptions as to the availability and efficacy of various therapies projected that the infection could become rare by 2026, according to a report published online in the Annals of Internal Medicine.

MOC changes haven’t quieted uprising
The American Board of Internal Medicine is making several changes to its maintenance of certification requirements, but, so far, it is not enough to quell the still growing tide of anger and resentment against the process.

New HCV drugs could boost Part D spending by $5.8 billion
New treatments for hepatitis C could boost federal spending for the Medicare Part D program by up to $5.8 billion in 2015 and lead to a 4.3%-8.6% premium increase for beneficiaries, according to a report by the actuarial firm Milliman, prepared for the Pharmaceutical Care Management Association.

FDA approves DNA stool test for CRC screening
The Food and Drug Administration has approved another noninvasive alternative to colonoscopy for screening for colorectal cancer, this one a stool-based test that detects the presence of red blood cells and DNA mutations.

PDF | Interactive Version